Senshio (ospemifene)
- Region
- 🇪🇺 EU
- Active substance
- ospemifene
- Company
- Shionogi B.V.
- Status
- Authorised
- Therapeutic area
- Postmenopause
- EU approval
- Wed 14 Jan 2015
- Application
- EMEA/H/C/002780
- ATC
- G03XC05
- Official record
- www.ema.europa.eu
Indication
Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women.
Regulatory milestones
No milestones recorded in the last year.
Follow Senshio
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.